FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:870-878 September 20, 2001 Number 12 Next

	Full Text PDF Editorial by Hostetter, T. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Microalbuminuria and hypertension are risk factors for diabetic nephropathy. Blockade of the renin–angiotensin system slows the progression to diabetic nephropathy in patients with type 1 diabetes, but similar data are lacking for hypertensive patients with type 2 diabetes. We evaluated the renoprotective effect of the angiotensin-II–receptor antagonist irbesartan in hypertensive patients with type 2 diabetes and microalbuminuria.

Methods A total of 590 hypertensive patients with type 2 diabetes and microalbuminuria were enrolled in this multinational, randomized, double-blind, placebo-controlled study of irbesartan, at a dose of either 150 mg daily or 300 mg daily, and were followed for two years. The primary outcome was the time to the onset of diabetic nephropathy, defined by persistent albuminuria in overnight specimens, with a urinary albumin excretion rate that was greater than 200 µg per minute and at least 30 percent higher than the base-line level.

Results The base-line characteristics in the three groups were similar. Ten of the 194 patients in the 300-mg group (5.2 percent) and 19 of the 195 patients in the 150-mg group (9.7 percent) reached the primary end point, as compared with 30 of the 201 patients in the placebo group (14.9 percent) (hazard ratios, 0.30 [95 percent confidence interval, 0.14 to 0.61; P<0.001] and 0.61 [95 percent confidence interval, 0.34 to 1.08; P=0.08] for the two irbesartan groups, respectively). The average blood pressure during the course of the study was 144/83 mm Hg in the placebo group, 143/83 mm Hg in the 150-mg group, and 141/83 mm Hg in the 300-mg group (P=0.004 for the comparison of systolic blood pressure between the placebo group and the combined irbesartan groups). Serious adverse events were less frequent among the patients treated with irbesartan (P=0.02).

Conclusions Irbesartan is renoprotective independently of its blood-pressure–lowering effect in patients with type 2 diabetes and microalbuminuria.

Source Information

From the Steno Diabetes Center, Copenhagen, Denmark (H.-H.P., S.A.); the Department of Endocrinology and Metabolism, Magdeburg University Medical School, Magdeburg, Germany (H.L.); the Department of Clinical Physiology, Aalborg Hospital, Aalborg, Denmark (J.B.-M.); the Department of Endocrinology, University of Barcelona, Barcelona, Spain (R.G.); and the Department of Medicine, Huddinge Hospital, Huddinge, Sweden (P.A.).

Address reprint requests to Dr. Parving at the Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark.

Full Text of this Article

This article has been cited by other articles:

• Schindler, C. (2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Therapeutic Advances in Cardiovascular Disease 2: 233-248 [Abstract]  
• de Jong, P. E., Gansevoort, R. T. (2008). Reply. Nephrol Dial Transplant 23: 2698-2699 [Full Text]  
• Satoh, M., Fujimoto, S., Arakawa, S., Yada, T., Namikoshi, T., Haruna, Y., Horike, H., Sasaki, T., Kashihara, N. (2008). Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 0: gfn357v1-gfn357 [Abstract] [Full Text]  
• Carey, R. M. (2008). Antihypertensive and Renoprotective Mechanisms of Renin Inhibition in Diabetic Rats. Hypertension 52: 63-64 [Full Text]  
• Farbom, P., Wahlstrand, B., Almgren, P., Skrtic, S., Lanke, J., Weiss, L., Kjeldsen, S., Hedner, T., Melander, O. (2008). Interaction Between Renal Function and Microalbuminuria for Cardiovascular Risk in Hypertension: The Nordic Diltiazem Study. Hypertension 52: 115-122 [Abstract] [Full Text]  
• Fisher, N. D.L., Jan Danser, A.H., Nussberger, J., Dole, W. P., Hollenberg, N. K. (2008). Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans. Circulation 117: 3199-3205 [Abstract] [Full Text]  
• Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K., the AVOID Study Investigators, (2008). Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. NEJM 358: 2433-2446 [Abstract] [Full Text]  
• Heerspink, H. L., Greene, T., Lewis, J. B., Raz, I., Rohde, R. D., Hunsicker, L. G., Schwartz, S. L., Aronoff, S., Katz, M. A., Eisner, G. M., Mersey, J. H., Wiegmann, T. B., for the Collaborative Study Group, (2008). Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 23: 1946-1954 [Abstract] [Full Text]  
• Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M., Sharma, S. K., Perna, A., Remuzzi, G. (2008). Role of Remission Clinics in the Longitudinal Treatment of CKD. J. Am. Soc. Nephrol. 19: 1213-1224 [Full Text]  
• Galle, J., Schwedhelm, E., Pinnetti, S., Boger, R. H., Wanner, C., on behalf of the VIVALDI investigators, (2008). Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 0: gfn230v1-gfn230 [Abstract] [Full Text]  
• Mitterbauer, C., Heinze, G., Kainz, A., Kramar, R., Horl, W. H., Oberbauer, R. (2008). ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 23: 1742-1746 [Abstract] [Full Text]  
• Postma, M. J., Boersma, C., Gansevoort, R. T. (2008). Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrol Dial Transplant 23: 1103-1106 [Full Text]  
• Salanti, G., Kavvoura, F. K., Ioannidis, J. P.A. (2008). Exploring the Geometry of Treatment Networks. ANN INTERN MED 148: 544-553 [Abstract] [Full Text]  
• Kelly, C. J., Booth, G. (2008). Pharmacist-led structured care for patients with diabetic nephropathy. British Journal of Diabetes & Vascular Disease 8: 86-88 [Abstract]  
• Izuhara, Y., Nangaku, M., Takizawa, S., Takahashi, S., Shao, J., Oishi, H., Kobayashi, H., van Ypersele de Strihou, C., Miyata, T. (2008). A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23: 497-509 [Abstract] [Full Text]  
• Huang, Y., Border, W. A., Yu, L., Zhang, J., Lawrence, D. A., Noble, N. A. (2008). A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy. J. Am. Soc. Nephrol. 19: 329-338 [Abstract] [Full Text]  
• de Zeeuw, D., Raz, I. (2008). Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes. Diabetes Care 31: S190-S193 [Full Text]  
• Basi, S., Fesler, P., Mimran, A., Lewis, J. B. (2008). Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander?. Diabetes Care 31: S194-S201 [Full Text]  
• Kunz, R., Friedrich, C., Wolbers, M., Mann, J. F.E. (2008). Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. ANN INTERN MED 148: 30-48 [Abstract] [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• Uresin, Y., Taylor, A. A, Kilo, C., Tschope, D., Santonastaso, M., Ibram, G., Hui Fang, , Satlin, A. (2007). Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of Renin-Angiotensin-Aldosterone System 8: 190-200 [Abstract]  
• Burnier, M. (2007). Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective. Journal of Renin-Angiotensin-Aldosterone System 8: 208-211  
• Zandbergen, A. A.M., Vogt, L., de Zeeuw, D., Lamberts, S. W.J., Ouwendijk, R. J.T.H., Baggen, M. G.A., Bootsma, A. H. (2007). Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care 30: 3119-3121 [Full Text]  
• Whaley-Connell, A., Pavey, B. S., Chaudhary, K., Saab, G., Sowers, J. R. (2007). Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Therapeutic Advances in Cardiovascular Disease 1: 27-35 [Abstract]  
• Lamb, E. J., Fogarty, D. G., Murchie, P., Ritz, E., Isles, C., Jardine, A., Goldsmith, D., Cassidy, M., O'Donoghue, D., McIntyre, N., Vale, L., Feehally, J., El Nahas, M. (2007). Speaker Abstracts: Tuesday, 6 February 2007. Nephrol Dial Transplant 22: ix45-ix53 [Full Text]  
• Hardy, K. J, Furlong, N. J, Hulme, S. A, O'Brien, S. V (2007). Delivering improved management and outcomes in diabetic kidney disease in routine clinical care. British Journal of Diabetes & Vascular Disease 7: 172-182 [Abstract]  
• Jin, H.-M., Pan, Y. (2007). Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant 22: 1943-1949 [Abstract] [Full Text]  
• Boulanger, H., Mansouri, R., Gautier, J. F., Glotz, D. (2007). Reply--PPAR agonists in diabetic nephropathy. Nephrol Dial Transplant 22: 2095-2096 [Full Text]  
• Campbell, H. M, Boardman, K. D, Dodd, M. A, Raisch, D. W (2007). Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model. The Annals of Pharmacotherapy 41: 1101-1110 [Abstract] [Full Text]  
• Wang, J.-G., Li, Y., Franklin, S. S., Safar, M. (2007). Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview. Hypertension 50: 181-188 [Abstract] [Full Text]  
• Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 0: ehm236v1-75 [Full Text]  
• Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., for the INNOVATION Study Group, (2007). Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes. Diabetes Care 30: 1577-1578 [Full Text]  
• Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., Levey, A. S., for the AIRPD Study Group, (2007). Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. J. Am. Soc. Nephrol. 18: 1959-1965 [Abstract] [Full Text]  
• Hou, F. F., Xie, D., Zhang, X., Chen, P. Y., Zhang, W. R., Liang, M., Guo, Z. J., Jiang, J. P. (2007). Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency. J. Am. Soc. Nephrol. 18: 1889-1898 [Abstract] [Full Text]  
• Weir, M. R. (2007). Microalbuminuria and Cardiovascular Disease. CJASN 2: 581-590 [Abstract] [Full Text]  
• Lewis, J. (2007). Treating Diabetic Nephropathy: Unfinished Success Is Not Failure. CJASN 2: 407-409 [Full Text]  
• Chudleigh, R. A., Dunseath, G., Evans, W., Harvey, J. N., Evans, P., Ollerton, R., Owens, D. R. (2007). How Reliable Is Estimation of Glomerular Filtration Rate at Diagnosis of Type 2 Diabetes?. Diabetes Care 30: 300-305 [Abstract] [Full Text]  
• Hartner, A., Cordasic, N., Klanke, B., Wittmann, M., Veelken, R., Hilgers, K. F. (2007). Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am. J. Physiol. Renal Physiol. 292: F820-F827 [Abstract] [Full Text]  
• Savoia, C., Touyz, R. M., Volpe, M., Schiffrin, E. L. (2007). Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. Hypertension 49: 341-346 [Abstract] [Full Text]  
• Hovind, P., Lamberts, S., Hop, W., Deinum, J., Tarnow, L., Parving, H.-H., Janssen, J. A M J L (2007). An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. Eur J Endocrinol 156: 83-90 [Abstract] [Full Text]  
• Ruggenenti, P., Remuzzi, G. (2007). Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health. CJASN 2: 146-150 [Full Text]  
• American Diabetes Association, (2007). Standards of Medical Care in Diabetes--2007. Diabetes Care 30: S4-S41 [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation 114: 2871-2891 [Full Text]  
• Persson, F., Rossing, P., Hovind, P., Stehouwer, C. D.A., Schalkwijk, C., Tarnow, L., Parving, H.-H. (2006). Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. Diabetes 55: 3550-3555 [Abstract] [Full Text]  
• Glassock, R. J. (2006). Prevention of Microalbuminuria in Type 2 Diabetes: Millimeters or Milligrams?. J. Am. Soc. Nephrol. 17: 3276-3278 [Full Text]  
• Marin, R., Rodriguez, P., Tranche, S., Redon, J., Morales-Olivas, F., Galgo, A., Brito, M. A., Mediavilla, J., Lozano, J. V., Filozof, C., the MAGAL group, (2006). Prevalence of Abnormal Urinary Albumin Excretion Rate in Hypertensive Patients with Impaired Fasting Glucose and Its Association with Cardiovascular Disease. J. Am. Soc. Nephrol. 17: S178-S188 [Abstract] [Full Text]  
• Guo, C., Martinez-Vasquez, D., Mendez, G. P., Toniolo, M. F., Yao, T. M., Oestreicher, E. M., Kikuchi, T., Lapointe, N., Pojoga, L., Williams, G. H., Ricchiuti, V., Adler, G. K. (2006). Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus. Endocrinology 147: 5363-5373 [Abstract] [Full Text]  
• Winkelmayer, W. C., Zhang, Z., Shahinfar, S., Cooper, M. E., Avorn, J., Brenner, B. M. (2006). Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes. Diabetes Care 29: 2210-2217 [Abstract] [Full Text]  
• Rossing, P., Parving, H.-H., de Zeeuw, D. (2006). Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?. Nephrol Dial Transplant 21: 2354-2357 [Full Text]  
• Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., Beckerman, B. (2006). Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes. CJASN 1: 940-951 [Abstract] [Full Text]  
• Hollenberg, N. K., Epstein, M. (2006). Renin Angiotensin System Blockade and Nephropathy: Why Is It Being Called into Question, and Should It Be?. CJASN 1: 1046-1048 [Full Text]  
• Johnson, S. L., Tierney, E. F., Onyemere, K. U., Tseng, C.-W., Safford, M. M., Karter, A. J., Ferrara, A., Duru, O. K., Brown, A. F., Narayan, K.M. V., Thompson, T. J., Herman, W. H. (2006). Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment?: The Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 29: 1733-1738 [Abstract] [Full Text]  
• Tonelli, M., Sacks, F., Pfeffer, M., Gao, Z.H., Curhan, G., for the Cholesterol and Recurrent Events (CARE) Tr, , Rossing, P., Rossing, K., Gaede, P., Pedersen, O., Parving, H.-H. (2006). Serum Phosphate: A Novel Cardiovascular Risk Factor Even in Nonrenal Patients: Relation between Serum Phosphate Level and Cardiovascular Event Rate in People with Coronary Disease. Circulation 112: 2627-2633, 2005. J. Am. Soc. Nephrol. 17: 2077-2085 [Full Text]  
• de Jong, P. E., Curhan, G. C. (2006). Screening, Monitoring, and Treatment of Albuminuria: Public Health Perspectives. J. Am. Soc. Nephrol. 17: 2120-2126 [Abstract] [Full Text]  
• de Zeeuw, D., Parving, H.-H., Henning, R. H. (2006). Microalbuminuria as an Early Marker for Cardiovascular Disease. J. Am. Soc. Nephrol. 17: 2100-2105 [Abstract] [Full Text]  
• Sacco, R. L., Goldstein, L. B. (2006). Response to Letter by Mysak et al. Stroke 37: 1968-1968 [Full Text]  
• Savoia, C., Touyz, R. M., Endemann, D. H., Pu, Q., Ko, E. A., De Ciuceis, C., Schiffrin, E. L. (2006). Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. Hypertension 48: 271-277 [Abstract] [Full Text]  
• Kanno, Y., Takenaka, T., Nakamura, T., Suzuki, H. (2006). Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors. CJASN 1: 730-737 [Abstract] [Full Text]  
• Balasubramanyam, A., Hinnen, D., Polonsky, W. (2006). Cardiovascular Event Prevention in the Person With Type 2 Diabetes: Case Examples for Identifying and Treating Multiple Risks. The Diabetes Educator 32: 163S-173S [Full Text]  
• Dobesh, P. P. (2006). Managing hypertension in patients with type 2 diabetes mellitus.. Am J Health Syst Pharm 63: 1140-1149 [Abstract] [Full Text]  
• Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G. L., Catena, C. (2006). Long-term renal outcomes in patients with primary aldosteronism.. JAMA 295: 2638-2645 [Abstract] [Full Text]  
• Haller, H., Park, J.-K., Lindschau, C., Meyer, M., Menne, J. (2006). Intrarenal renin-angiotensin system -- important player of the local milieu. Journal of Renin-Angiotensin-Aldosterone System 7: 122-125  
• Oudit, G. Y., Herzenberg, A. M., Kassiri, Z., Wong, D., Reich, H., Khokha, R., Crackower, M. A., Backx, P. H., Penninger, J. M., Scholey, J. W. (2006). Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis. Am. J. Pathol. 168: 1808-1820 [Abstract] [Full Text]  
• Mccallum, R. W, Fisher, M. (2006). Review: Comparing cardiovascular outcomes in diabetes studies. British Journal of Diabetes & Vascular Disease 6: 111-118 [Abstract]  
• Andreas, S., Herrmann-Lingen, C., Raupach, T., Luthje, L., Fabricius, J. A., Hruska, N., Korber, W., Buchner, B., Criee, C-P., Hasenfuss, G., Calverley, P. (2006). Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 27: 972-979 [Abstract] [Full Text]  
• Humpert, P. M., Kopf, S., Djuric, Z., Wendt, T., Morcos, M., Nawroth, P. P., Bierhaus, A. (2006). Plasma sRAGE Is Independently Associated With Urinary Albumin Excretion in Type 2 Diabetes. Diabetes Care 29: 1111-1113 [Full Text]  
• Miyata, T., van Ypersele de Strihou, C. (2006). Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering. Nephrol Dial Transplant 21: 846-849 [Full Text]  
• Konoshita, T., Wakahara, S., Mizuno, S., Motomura, M., Aoyama, C., Makino, Y., Kawai, Y., Kato, N., Koni, I., Miyamori, I., Mabuchi, H. (2006). Tissue Gene Expression of Renin-Angiotensin System in Human Type 2 Diabetic Nephropathy. Diabetes Care 29: 848-852 [Abstract] [Full Text]  
• Sugaru, E., Nakagawa, T., Ono-Kishino, M., Nagamine, J., Tokunaga, T., Kitoh, M., Hume, W. E., Nagata, R., Taiji, M. (2006). SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am. J. Physiol. Renal Physiol. 290: F813-F820 [Abstract] [Full Text]  
• Volpe, M., Tocci, G., Pagannone, E. (2006). Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.. J. Am. Soc. Nephrol. 17: S36-S43 [Abstract] [Full Text]  
• Remuzzi, G., Macia, M., Ruggenenti, P. (2006). Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study. J. Am. Soc. Nephrol. 17: S90-S97 [Abstract] [Full Text]  
• Ravera, M., Re, M., Deferrari, L., Vettoretti, S., Deferrari, G. (2006). Importance of Blood Pressure Control in Chronic Kidney Disease. J. Am. Soc. Nephrol. 17: S98-S103 [Abstract] [Full Text]  
• Barnett, A. (2006). Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial. J. Am. Soc. Nephrol. 17: S132-S135 [Abstract] [Full Text]  
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e409-e449 [Abstract] [Full Text]  
• Ferrario, C. M (2006). Role of Angiotensin II in Cardiovascular Disease -- Therapeutic Implications of More Than a Century of Research. Journal of Renin-Angiotensin-Aldosterone System 7: 3-14 [Abstract]  
• Vora, J., Weston, C. (2006). BENEDICT: primary prevention of microalbuminuria in hypertensive type 2 diabetes: Bergamo NEphrologic Diabetes Complication Trial (BENEDICT). British Journal of Diabetes & Vascular Disease 6: 84-88  
• Cao, C., Hellermann, J. P., Weber, M., Ambuhl, P. M. (2006). Time trends in the epidemiology of renal transplant patients with type 1 diabetes mellitus over the last four decades. Nephrol Dial Transplant 21: 770-775 [Abstract] [Full Text]  
• Sasso, F. C., De Nicola, L., Carbonara, O., Nasti, R., Minutolo, R., Salvatore, T., Conte, G., Torella, R., for the NID-2 (Nephropathy in Diabetes-Type 2) Stu, (2006). Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy.. Diabetes Care 29: 498-503 [Abstract] [Full Text]  
• Ibsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlof, B., Snapinn, S. M., Wan, Y., Lyle, P. A. (2006). Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study.. Diabetes Care 29: 595-600 [Abstract] [Full Text]  
• Jayapaul, M.K., Messersmith, R., Bennett-Jones, D.N., Mead, P.A., Large, D.M. (2006). The joint diabetic-renal clinic in clinical practice: 10 years of data from a District General Hospital. QJM 99: 153-160 [Abstract] [Full Text]  
• Nickenig, G., Ostergren, J., Struijker-Boudier, H. (2006). Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers. Journal of Renin-Angiotensin-Aldosterone System 7: S1-S7 [Abstract]  
• Barnett, A. H (2006). The challenge of tackling cardiovascular outcomes. British Journal of Diabetes & Vascular Disease 6: S12-S16 [Abstract]  
• Fisher, M., Campbell, I. W (2006). Residual cardiovascular risk and practical management of type 2 diabetes. British Journal of Diabetes & Vascular Disease 6: S17-S23 [Abstract]  
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 577-617 [Abstract] [Full Text]  
• Houweling, S., Kleefstra, N, Lutgers, H., Groenier, K., Jong, B M.-d., Bilo, H. (2006). Pitfalls in blood pressure measurement in daily practice. Fam Pract 23: 20-27 [Abstract] [Full Text]  
• Caramori, M. L., Fioretto, P., Mauer, M. (2006). Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy. J. Am. Soc. Nephrol. 17: 339-352 [Abstract] [Full Text]  
• De, P., Das, G., Harley, K., Nair, H. (2006). Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience. British Journal of Diabetes & Vascular Disease 6: 23-28 [Abstract]  
• Hall, P. M. (2006). Prevention of Progression in Diabetic Nephropathy. Diabetes Spectr. 19: 18-24 [Abstract] [Full Text]  
• Berl, T., Henrich, W. (2006). Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. CJASN 1: 8-18 [Full Text]  
• American Diabetes Association, (2006). Standards of Medical Care in Diabetes-2006. Diabetes Care 29: S4-S42 [Full Text]